154 related articles for article (PubMed ID: 37555463)
1. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Lück HJ; Schmidt M; Hesse T; Hoffmann O; Heinrich BJ; Park-Simon TW; Grischke EM; Weide R; Müller-Huesmann H; Lüdtke-Heckenkamp K; Fischer D; Zemlin C; Kögel M; Wu J; Schmitz H; Engelbrecht C; Jackisch C
Oncologist; 2023 Dec; 28(12):e1152-e1159. PubMed ID: 37555463
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
Vahdat LT; Garcia AA; Vogel C; Pellegrino C; Lindquist DL; Iannotti N; Gopalakrishna P; Sparano JA
Breast Cancer Res Treat; 2013 Jul; 140(2):341-51. PubMed ID: 23877339
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Tsurutani J; Sakata Y; Matsuoka T
Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
[TBL] [Abstract][Full Text] [Related]
5. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Acta Oncol; 2015 Apr; 54(4):522-9. PubMed ID: 25383448
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N; Damia G; Garrone O; Santini D; Fabi A; Ciccarese M; Generali DG; Nunzi M; Poletto E; Ferraris E; Cretella E; Scandurra G; Meattini I; Bertolini AS; Cavanna L; Collovà E; Romagnoli E; Rulli E; Legramandi L; Guffanti F; Bramati A; Moretti A; Cassano A; Vici P; Torri V; Farina G;
Breast Cancer Res; 2022 Oct; 24(1):71. PubMed ID: 36307826
[TBL] [Abstract][Full Text] [Related]
8. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
9. Eribulin.
Perry CM
Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
11. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
[TBL] [Abstract][Full Text] [Related]
12. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
13. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
Wozniak KM; Wu Y; Farah MH; Littlefield BA; Nomoto K; Slusher BS
Neurotox Res; 2013 Oct; 24(3):338-44. PubMed ID: 23637052
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.
Zhao B; Zhao H; Zhao J
Crit Rev Oncol Hematol; 2018 Aug; 128():110-117. PubMed ID: 29958626
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
16. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
Wu Y; Wang Q; Zhang J; Cao J; Wang B; Hu X
Support Care Cancer; 2020 Aug; 28(8):3819-3829. PubMed ID: 31832821
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
18. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
20. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study.
Kenny L; Beresford M; Brown I; Misra V; Kristeleit H
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13747. PubMed ID: 36336468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
